Combination therapy with BRMs in cancer and infectious diseases

Enrico Garaci, Francesca Pica, Guido Rasi, Anna T. Palamara, Cartesio Favalli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.

Original languageEnglish
Pages (from-to)103-116
Number of pages14
JournalMechanisms of Ageing and Development
Volume96
Issue number1-3
DOIs
Publication statusPublished - Jun 1997

Fingerprint

Immunologic Factors
Communicable Diseases
Tumors
Thymosin
Chemotherapy
Cytostatic Agents
Interleukin-2
Antiviral Agents
Neoplasms
Aging of materials
Theoretical Models
Therapeutics
Immunotherapy
Immunosuppression
Human Influenza
HIV
Drug Therapy
Growth

Keywords

  • Biological response modifiers (BRMs)
  • Infectious diseases
  • Thymosin α-1

ASJC Scopus subject areas

  • Ageing
  • Biochemistry
  • Developmental Biology
  • Developmental Neuroscience

Cite this

Combination therapy with BRMs in cancer and infectious diseases. / Garaci, Enrico; Pica, Francesca; Rasi, Guido; Palamara, Anna T.; Favalli, Cartesio.

In: Mechanisms of Ageing and Development, Vol. 96, No. 1-3, 06.1997, p. 103-116.

Research output: Contribution to journalArticle

Garaci, Enrico ; Pica, Francesca ; Rasi, Guido ; Palamara, Anna T. ; Favalli, Cartesio. / Combination therapy with BRMs in cancer and infectious diseases. In: Mechanisms of Ageing and Development. 1997 ; Vol. 96, No. 1-3. pp. 103-116.
@article{6275f0bddda4486cb93c135c1c8f1a1b,
title = "Combination therapy with BRMs in cancer and infectious diseases",
abstract = "In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.",
keywords = "Biological response modifiers (BRMs), Infectious diseases, Thymosin α-1",
author = "Enrico Garaci and Francesca Pica and Guido Rasi and Palamara, {Anna T.} and Cartesio Favalli",
year = "1997",
month = "6",
doi = "10.1016/S0047-6374(97)01895-2",
language = "English",
volume = "96",
pages = "103--116",
journal = "Mechanisms of Ageing and Development",
issn = "0047-6374",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Combination therapy with BRMs in cancer and infectious diseases

AU - Garaci, Enrico

AU - Pica, Francesca

AU - Rasi, Guido

AU - Palamara, Anna T.

AU - Favalli, Cartesio

PY - 1997/6

Y1 - 1997/6

N2 - In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.

AB - In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.

KW - Biological response modifiers (BRMs)

KW - Infectious diseases

KW - Thymosin α-1

UR - http://www.scopus.com/inward/record.url?scp=0030922206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030922206&partnerID=8YFLogxK

U2 - 10.1016/S0047-6374(97)01895-2

DO - 10.1016/S0047-6374(97)01895-2

M3 - Article

C2 - 9223114

AN - SCOPUS:0030922206

VL - 96

SP - 103

EP - 116

JO - Mechanisms of Ageing and Development

JF - Mechanisms of Ageing and Development

SN - 0047-6374

IS - 1-3

ER -